Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 6.84%, which has investors questioning if this is right ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...

Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $71 and keeps a Buy rating on ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.

Arcturus Therapeutics (ARCT) announced that the FDA has granted fast track designation for the self-amplifying mRNA vaccine candidate, ...

Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 Arcturus Therapeutics Holdings Inc. (the ...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities ...